Condition: Lung Non-Small Cell Carcinoma · Sponsor: SWOG Cancer Research Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Sutter Auburn Faith Hospital | Auburn, California, United States | Recruiting |
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley, California, United States | Recruiting |
| Palo Alto Medical Foundation-Fremont | Fremont, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Loma Linda University Medical Center | Loma Linda, California, United States | Recruiting |
| Memorial Medical Center | Modesto, California, United States | Recruiting |
| Palo Alto Medical Foundation Health Care | Palo Alto, California, United States | Suspended |
| Eisenhower Medical Center | Rancho Mirage, California, United States | Recruiting |
| Sutter Roseville Medical Center | Roseville, California, United States | Recruiting |
| Sutter Medical Center Sacramento | Sacramento, California, United States | Recruiting |
+ 236 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06116682